Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

A dose of an experimental drug reduced the levels of a fatal type of cholesterol for up to a year despite previous knowledge that it's untreatable. NBC News reported that pharmaceutical company Eli ...